Viking soars on ear­ly-stage weight loss da­ta as it maps out PhII

Viking Ther­a­peu­tics will en­ter the next phase of the GLP-1 weight loss race, as the small biotech tout­ed ear­ly da­ta show­ing its in­ves­ti­ga­tion­al drug led to a drop of as much as 6% more body weight than a place­bo.

With re­search still in the be­gin­ning stages of hu­man test­ing, Viking’s drug will re­quire more fleshed-out da­ta in a Phase II clin­i­cal tri­al, which the San Diego biotech said will start in the mid­dle of this year. Viking hopes the da­ta will help carve a slice of a mar­ket dom­i­nat­ed by No­vo Nordisk and Eli Lil­ly, with Am­gen on their heels and Al­tim­mune try­ing to push for­ward de­spite dis­pleas­ing in­vestors last week. The com­pa­nies are de­vel­op­ing drugs that have caused a fren­zy on so­cial me­dia, in Hol­ly­wood and in broad­er con­ver­sa­tions about weight loss drugs and their place in so­ci­ety.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER